Evolus, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Moatazedi
- Full Time Employees
- 353
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 520 Newport Center Drive Newport Beach CA United States of America 92660
- IPO Date
- Feb 8, 2018
- CIK
- 0001570562
- Website
- evolus.com
- Similar Companies
- Business
- Evolus, Inc. Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, develops and commercializes aesthetic products in the cash-pay medical aesthetics market, including proprietary neurotoxin and dermal filler brands; its flagship Jeuveau (prabotulinumtoxinA-xvfs), a 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement of moderate to severe glabellar lines in adults, marketed as Nuceiva internationally; and Evolysse, a portfolio of injectable hyaluronic acid gels featuring Cold-X Technology for dynamic facial wrinkles such as nasolabial folds, with Estyme as the international counterpart. The company operates primarily in the United States, Canada, Europe including Great Britain, Germany and Austria, and Australia, targeting aesthetic practitioners such as dermatologists, plastic surgeons and medical spas, as well as cash-paying consumers, through a customer-centric model supported by digital platforms like the Evolus Practice App and Evolus Rewards loyalty program. Founded in 2012 and headquartered in Newport Beach, California, Evolus sources manufacturing from Daewoong Pharmaceutical Co., Ltd. in South Korea and focuses on commercialization rather than in-house production. In recent developments, Evolus launched Evolysse in the U.S. in 2025, achieving rapid sell-out of initial inventory and projecting it to contribute 10-12% of full-year revenue amid reaffirmed 2025 net revenue guidance of $295-$305 million; the company attained profitability in Q4 2024 and full-year 2024, ahead of schedule, driven by over 30% revenue growth for the fifth consecutive year. Evolus continues international Nuceiva expansion and advances its multi-product portfolio to capture share in the $7.4 billion global neurotoxin and filler market projected by 2028, with gross margins reaching approximately 68% through scale efficiencies.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
Evolus (NASDAQ:EOLS) Reaches New 52-Week High – Time to Buy?
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
Evolus: The Injectable Platform Is Becoming The Real Moat
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus Q2 Earnings Call Highlights
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook